MX2017001453A - Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2). - Google Patents

Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).

Info

Publication number
MX2017001453A
MX2017001453A MX2017001453A MX2017001453A MX2017001453A MX 2017001453 A MX2017001453 A MX 2017001453A MX 2017001453 A MX2017001453 A MX 2017001453A MX 2017001453 A MX2017001453 A MX 2017001453A MX 2017001453 A MX2017001453 A MX 2017001453A
Authority
MX
Mexico
Prior art keywords
compounds
dihydropyrazolo
pyrazin
allosteric modulators
negative allosteric
Prior art date
Application number
MX2017001453A
Other languages
English (en)
Spanish (es)
Inventor
José Ignacio Andrés-Gil
Andrés Avelino Trabanco-Suárez
Gool Michiel Luc Maria Van
Óscar Delgado-González
Alvar Alonso-De Diego Sergio-
Isabel De Lucas Olivares Ana
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017001453A publication Critical patent/MX2017001453A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2017001453A 2014-08-01 2015-07-30 Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2). MX2017001453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179599 2014-08-01
PCT/EP2015/067533 WO2016016381A1 (en) 2014-08-01 2015-07-30 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

Publications (1)

Publication Number Publication Date
MX2017001453A true MX2017001453A (es) 2017-05-11

Family

ID=51257438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001453A MX2017001453A (es) 2014-08-01 2015-07-30 Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).

Country Status (15)

Country Link
US (1) US10112949B2 (enExample)
EP (1) EP3174880B1 (enExample)
JP (1) JP6615864B2 (enExample)
KR (1) KR102531693B1 (enExample)
CN (1) CN106573935B (enExample)
AR (1) AR101393A1 (enExample)
AU (1) AU2015295299B2 (enExample)
BR (1) BR112017001998A2 (enExample)
CA (1) CA2954218C (enExample)
EA (1) EA031038B1 (enExample)
ES (1) ES2702192T3 (enExample)
JO (1) JO3601B1 (enExample)
MX (1) MX2017001453A (enExample)
TW (1) TWI696625B (enExample)
WO (1) WO2016016381A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
CN107001375B (zh) 2014-12-03 2020-06-09 詹森药业有限公司 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
HUE050665T2 (hu) * 2015-12-18 2020-12-28 Janssen Pharmaceutica Nv Radiojelzett MGLUR2/3 PET ligandumok
MY201041A (en) 2017-11-24 2024-01-31 Sumitomo Pharma Co Ltd Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP1863818B1 (en) * 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
KR20140088887A (ko) 2011-11-03 2014-07-11 머크 샤프 앤드 돔 코포레이션 mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20130345205A1 (en) * 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192347A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
KR20150023822A (ko) * 2012-06-20 2015-03-05 벤더르빌트 유니버시티 Mglur5 수용체의 알로스테릭 조절물질로서 치환된 바이사이클릭 알콕시 피라졸 유사체
RU2015116749A (ru) 2012-10-23 2016-12-20 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения аутических расстройств
JP6517340B2 (ja) * 2014-08-01 2019-05-22 ヤンセン ファーマシューティカ エヌ.ベー. 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用

Also Published As

Publication number Publication date
JO3601B1 (ar) 2020-07-05
CA2954218C (en) 2022-11-29
CN106573935B (zh) 2020-01-17
CN106573935A (zh) 2017-04-19
JP2017523201A (ja) 2017-08-17
US20180222908A1 (en) 2018-08-09
CA2954218A1 (en) 2016-02-04
TWI696625B (zh) 2020-06-21
US10112949B2 (en) 2018-10-30
EA201692496A1 (ru) 2017-06-30
AU2015295299B2 (en) 2019-05-02
ES2702192T3 (es) 2019-02-27
KR102531693B1 (ko) 2023-05-10
KR20170032464A (ko) 2017-03-22
EP3174880B1 (en) 2018-09-26
BR112017001998A2 (pt) 2017-12-12
EP3174880A1 (en) 2017-06-07
EA031038B1 (ru) 2018-11-30
AU2015295299A1 (en) 2017-01-19
WO2016016381A1 (en) 2016-02-04
AR101393A1 (es) 2016-12-14
JP6615864B2 (ja) 2019-12-04
TW201609742A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
PH12017500161A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12015502685A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PH12017500170A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
MX2017001453A (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
NZ723103A (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
MY193728A (en) Muscarinic receptor agonists
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
TW201613864A (en) Novel compounds
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
TN2020000009A1 (en) Estrogen receptor modulators
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
IN2013MU03838A (enExample)
MA39583A1 (fr) Composés 6,7-dihydropyrazolo[1,5-a] pyrazin-4(5h)-one et leur utilisation comme modulateurs allostériques négatifs des récepteurs mglur2

Legal Events

Date Code Title Description
FG Grant or registration